Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the united states and globally

Emerging Infectious Diseases

Volumn 17, Issue 3, 2011, Pages 337-342

  Castro, Kenneth G ^a   Lobue, Philip ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

AMBITION GAP; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLOBAL CHANGE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HOLISTIC CARE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMPLEMENTATION GAP; INFORMATION DISSEMINATION; KNOWLEDGE GAP; MEDICAL EDUCATION; MEDICAL PRACTICE; MOLECULAR BIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PUBLIC HEALTH; THEORY-PRACTICE RELATIONSHIP; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; UNITED STATES; VIRULENCE; WORLD HEALTH;

EID: 79952354236     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1703.110031     Document Type: Article

References (38)

1. Koch R. Die Aetiologie der Tuberculose: Berliner Klinische Wochenschrift 1882;19:221-30. Pinner B, Pinner M, translators. Am Rev Tuberc. 1932;25:298-323.
2. The World Bank. Country and Lending Groups [cited 2011 Jan 1]. http://data.worldbank.org/about/country-classifications/countryand-lending-groups
3. World Health Organization. Global tuberculosis control 2010 [cited 2011 Jan 3]. http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf
4. World Health Organization. Global tuberculosis control: a short update to the 2009 report [cited 2011 Jan 3]. http://whqlibdoc.who.int/publications/2009/9789241598866_eng.pdf
5. Fox W. Realistic chemotherapeutic policies for tuberculosis in the developing countries. BMJ. 1964;1:135-142. DOI: 10.1136/ bmj.1.5376.135
6. Fendall NR. Auxiliaries and primary medical care. Bull N Y Acad Med. 1972;48:1291-300.
7. Fox W. Pillip Ellman Lecture: The modern management and therapy of pulmonary tuberculosis. Proc R Soc Med. 1977;70:4-15.
8. Mount FW, Ferebee SH. United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis. V: report on thirty-two week observations on combinations of isoniazid, streptomycin, and para-amino salicylic acid. Am Rev Tuberc. 1954;70:521-6.
9. Rouillon A. The mutual assistance programme of the IUATLD. Development, contribution, and signifi cance. Bull Int Union Tuberc Lung Dis. 1991;66:159-72.
10. Raviglione MC, Uplekar M. WHO's new Stop TB strategy. Lancet. 2006;367:952-5. DOI: 10.1016/S0140-6736(06)68392-X
11. Komatsu R, Low-Beer D, Schwartlander B. Global Fund supported programmes' contribution to international targets and the Millennium Development Goals: an initial analysis. Bull World Health Organ. 2007;85:805-11. DOI: 10.2471/BLT.06.038315
12. Coggin WL, Ryan CA, Holmes CB. Role of the US President's emergency plan for AIDS relief in responding to tuberculosis and HIV coinfection. Clin Infect Dis. 2010;50(Suppl 3):S255-9. DOI: 10.1086/651499
13. Laxminarayan R, Klein EY, Adeyi O. Global investments in TB control: economic benefi ts. Health Aff (Millwood). 2009;28:w730-42. DOI: 10.1377/hlthaff.28.4.w730
14. World Health Organization. The global plan to stop TB 2011-2015: transforming the fi ght towards the elimination of tuberculosis [cited 2011 Jan 3]. http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf
15. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis. 2006;6:710-25. DOI: 10.1016/S1473-3099(06)70628-4
16. Lönnroth K, Castro KG, Chakayah JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010;375:1814-29. DOI: 10.1016/S0140-6736(10)60483-7
17. Pantoja A, Floyd K, Unnikrishnan KP, Jitendra R, Padma MR, Lal SS, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profi le and costs among tuberculosis patients. Int J Tuberc Lung Dis. 2009;13:698-704.
18. World Health Organization. WHO endorses new rapid tuberculosis test. 2010 [cited 2011 Jan 5]. http://www.who.int/tb/features_archive/new_rapid_test/en/index.html
19. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accuracy of commercially based nucleic acid amplifi cation tests for the diagnosis of pulmonary tuberculosis. Thorax. 2006;61:783-90. DOI: 10.1136/thx.2005.054908
20. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplifi cation tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 2008;3:e1536.
21. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-1015. DOI: 10.1056/ NEJMoa0907847
22. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79:3-29. DOI: 10.1054/tuld.1998.0002
23. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177:787-92. DOI: 10.1164/rccm.200709-1436OC
24. García de Viedma D. Rapid detection of resistance in Mycobacterium tuberculosis: a review discussing molecular approaches. Clin Microbiol Infect. 2003;9:349-359. DOI: 10.1046/j.1469- 0691.2003.00695.x
25. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, et al.; Tuberculosis Trials Consortium. Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis. 2009;15:1061-7. DOI: 10.3201/eid1507.081253
26. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173-80. DOI: 10.1016/S0140-6736(06)68507-3
27. Brewer TF. Preventing tuberculosis with bacillus Calmette- Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis. 2000;31(Suppl 3):S64-7. DOI: 10.1086/314072
28. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47.
29. American Thoracic Society, Infectious Diseases Society of America, Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(No. RR-11):1-77.
30. Sterling TR, Borisov AS, Shang N, Bliven-Sizemore E, Chaisson RE, Gordin F, et al. The PREVENT TB Study (TB Trials Consortium Study 26) of 3 months of once-weekly rifapentine plus INH vs. 9 months of daily INH for treatment of latent TB infection: fi rst report of results of a multi-center, randomized clinical trial. Symposium 44. The Union/CDC Late-breaker session on tuberculosis. 41st UNION World Conference on Lung Health; Berlin, Germany; November 15, 2010.
31. The Arden House Conference on Tuberculosis. US Department of Health, Education, and Welfare, Public Health Service. Publication no. 784. Washington: US Government Printing Offi ce; 1961.
32. Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 1989;38(S-3):1-25.
33. Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 1994;272:535-9. DOI: 10.1001/jama.272.7.535
34. Tuberculosis Task Force. National action plan to combat multidrug resistant tuberculosis. MMWR Recomm Rep. 1992;41(RR-11): 1-48.
35. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington: National Academies Press; 2000.
36. Dowdle WR. The principles of disease elimination and eradication. MMWR Morb Mortal Wkly Rep. 1999;48(Suppl 1):23-7.
37. Brown WJ. A plan for the eradication of syphilis. South Med J. 1963;56:840-3.
38. Time Magazine. Medicine: resurgent syphilis: it can be eradicated. 1962 [cited 2011 Jan 4]. http://www.time.com/time/magazine/article/0,9171,827568,00.html